ArticleJournal of translational medicine2026
Network-based single-cell analysis identifies a proliferative GZMB
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung squamous cell carcinoma (LUSC) is a heterogeneous cancer characterized by complex cellular interactions. Plasma cells, a critical immune population, exhibit functional diversity in LUSC. The aim of this study was to characterize plasma cell heterogeneity and their interactions with tumor cells using an integrative single-cell framework.
methodsWe constructed a high-resolution single-cell atlas of LUSC using single-cell RNA-sequencing data to identify plasma cell subsets. Plasma cell heterogeneity was assessed through clustering and differential expression analysis, and differentiation trajectories were plotted. Cell-cell communication was analyzed using the "CellChat" package. A prognostic nine-gene signature was derived using LASSO-Cox regression and further validated across independent GEO cohorts. Upstream regulatory mechanisms of prognostic genes were investigated through integrative transcriptomic analysis. The role of ZBTB20 in tumor progression was validated through functional assays.
resultsThree plasma cell subsets were identified, including a proliferative GZMB
conclusionsThe proliferative C2 plasma cell subset has prognostic and functional significance in LUSC. ZBTB20 regulates key tumor-related pathways in LUSC cells through UBB-centered transcriptional control. These findings provide a systems-level framework for understanding plasma cell dynamics and tumor-immune interactions in LUSC progression for future development of targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.